medigraphic.com
Colegio de Medicina Interna de México.

2025, Number 02

<< Back Next >>

Med Int Mex 2025; 41 (02)

Mexican Consensus Delphy for the indication of favipiravir to patients with COVID-19

Herrera GJC, Colli DAA, Galicia SLM, Vázquez CJJ, Buenfil GCM, Morett VF, Guzmán BNE; Hernández FN, Cuilty SC, López SGN, López LDA, Casillas SC, W Locela BE

Language: Spanish
References: 17
Page: 72-77
PDF size: 190.70 Kb.


ABSTRACT

Objective: To report the results of the Mexican Delphi consensus on the indication of favipiravir in patients with COVID-19.
Methodology: Based on the Delphi method, a group of specialists developed a questionnaire with questions regarding the benefit or otherwise of treatment with favipiravir for patients with COVID-19. This was done after diagnosis, identification of risk factors and comorbidities, and search for the ideal patient to receive the drug under study. Patients were followed up with laboratory and imaging studies.
Results: The consensus was concluded with 15 recommendations for the indication of favipiravir in patients with COVID-19 infection in Mexico for prescription at any level of medical care.
Conclusions: Favipiravir is a good treatment option for patients with COVID-19 pneumonia and comorbidities with strong clinical results in reducing symptoms and preventing disease progression in the short term. The data from this study show that there is a consensus on the need to prescribe favipiravir to patients with COVID-19 infection and at risk of disease progression. The consensus fulfills the established goals of having an initial document of evidence, by recommendation, regarding the indication of favipiravir for patients with COVID-19 infection.


REFERENCES

  1. Palmieri PA. La técnica Delphi: Un método de consenso parala investigación en servicios de salud en Latino América.Ágora Rev Cient 2017; 4 (2): e7. https://doi.org/10.21679/arc.v4i2.89

  2. Manabe, et al. BMC Infectious Diseases 2021; 21: 489.https://doi.org/10.1186/s12879-021-06164-x

  3. Cases AA. Consenso Delphi sobre el diagnóstico y manejode la dislipidemia en pacientes con enfermedad renalcrónica: análisis post-hoc del estudio DIANA. Nefrología2016; 36 (6): 679-686.

  4. Huang C, Wang Y, Li X, Ren L, et al. Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan.China Lancet 2020; 395 (10223): 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5

  5. World Health Organization. WHO Director-General’sopening remarks at the media briefing on COVID-19 - 11March 2020. https://www. who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-themediabriefing-on-covid-19%2D%2D-11-march-2020

  6. World Health Organization. Weekly epidemiologicalupdate-1 December 2020. https://www.who.int/publications/m/item/weeklyepidemiologicalupdate%2D%2D-1-december-2020

  7. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), abroad spectrum inhibitor of viral RNA polymerase. ProcJpn Acad Ser B Phys Biol Sci 2017; 93 (7): 449-63. https://doi.org/10.2183/pjab.93.027

  8. FUJIFILM Toyama Chemical Co., Ltd. Drug Interview form.Avigan® http:// fftc.fujifilm.co.jp/med/abigan/pack/pdf/abigan_if_01.pdf

  9. Lee JS, Adhikari NKJ, Kwon HY, Teo K, et al. Anti-Ebolatherapy for patients with Ebola virus disease: a systematicreview. BMC Infect Dis 2019; 19 (1): 376. https://doi.org/10.1186/s12879-019-3980-9

  10. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drugagainst life threatening RNA virus infections. PharmacolTher 2020; 209: 107512. https://doi.org/10.1016/j.pharmthera.2020.107512

  11. Eloy P, Solas C, Touret F, Mentré F, et al. Dose rationalefor favipiravir use in patients infected with SARS-CoV-2.Clin Pharmacol Ther 2020; 108 (2): 188. https://doi.org/10.1002/cpt.1877

  12. Hibino M, Hase R, Yamamoto M, Kasamatsu Y, et al. A prospective,randomized, open-label trial of early versus latefavipiravir therapy in hospitalized patients with COVID-19.Antimicrob Agents Chemother 2020; 64: e01897-20.https://doi.org/10.1128/AAC .01897-20

  13. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, PalavutitotaiN, et al. Real-World effectiveness and optimal dosage offavipiravir for treatment of COVID-19: Results from a multicenterobservational study in Thailand. Antibiotics 2022; 11:805. https://doi.org/10.3390/ antibiotics11060805

  14. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new andemerging antiviral option in COVID-19. MJ Armed ForcesIndia 2020; 76 (4):370-76. https://doi.org/10.1016/j.mjafi.2020.08.004

  15. Kazuma Y and Special Committee of theJapanese ClinicalPractice Guidelines for the Management of Sepsis andSeptic Shock 2020 (J-SSCG 2020), the COVID-19 Task Force.Japanese rapid/living recommendations on drug managementfor COVID-19: updated guidelines (July 2022). AcuteMedicine & Surgery 2022; 9: e789doi: 10.1002/ams2.789

  16. Holubar M, Subramaniam A, Purington N, Hedlin H, et al.Favipiravir for treatment of outpatients with asymptomaticor uncomplicated COVID-19: a 2 double-blind randomized,placebo-controlled, phase 2 trial. Clin Intect Dis 2022; 75(11): 1883-92. https://doi.org/10.1093/cid/ciac312

  17. Herrera-García JC, Arellano-Montellano EI, Juárez-GonzálezLI, Robles-Terrez G. Successful use of favipiravir in a comorbidpatient associated with COVID-19 Pneumoni. AmJ Biomed Sci & Res 2023; 19 (6). AJBSR.MS.ID.002651.




2020     |     www.medigraphic.com